By univariable analysis, Denkert et al. found that high tumor-infiltrating lymphocytes predicted longer disease-free survival in patients with HER2-positive breast cancer and TNBC treated with neoadjuvant therapy (Denkert et al., 2018). Here, ERBB2 is linked to neoplasm.